Lehman Repeats Buy on Decode Genetics

Analyst Ian Smith told S&P the company's latest discoveries prove it can find genes associated with important diseases

Decode Genetics (DCGN ) and its partner Roche announced identification of the stroke gene, and the location of the gene linked to Type 2 diabetes. Lehman Brothers reiterated its buy rating on shares of Decode.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.